In this episode of Raising Biotech, host Surani takes a deep dive into Alltrna, a biotech startup backed by Flagship Pioneering, that’s pioneering the use of transfer RNA (tRNA) technology to treat rare genetic diseases. With a recent $109 million Series B raise following its $50 million Series A, Alltrna is harnessing the potential of tRNA to develop universal therapies that could address hundreds—if not thousands—of genetic conditions. Surani speaks with CEO Michelle Werner and Dr. David Weinstein, a rare diseases expert, to explore the company’s groundbreaking science and their roadmap to the clinic.
Werner explains how Alltrna was founded to tackle genetic diseases caused by “stop codons,” mutations that prematurely halt protein production, leading to various genetic diseases. By engineering tRNAs to read through these faulty signals, Alltrna aims to restore the full-length protein and correct genetic errors. “Our goal is to make one medicine applicable across multiple diseases,” Werner says, highlighting the ambitious scope of their platform. Motivated by her own son’s diagnosis with Duchenne muscular dystrophy (DMD), Werner brings a personal commitment to the mission.
Alltrna is initially focusing on targeting liver diseases, which Dr Weinstein notes makes strategic sense. With over 400 monogenic liver diseases affecting millions worldwide, their tRNA approach could provide a safer and more effective alternative to current gene therapies, which often struggle with safety and delivery issues. He describes the tRNA strategy as “a game-changer” that could apply to many conditions without needing separate trials for each one.
The episode also covers Alltrna’s plan to use basket trials, a method borrowed from oncology, to run parallel studies across multiple diseases sharing the same genetic mutation. Werner’s background in oncology plays a crucial role here as the company looks to accelerate its clinical development timeline. Alltrna aims to launch clinical trials in the coming years, and while the journey is fraught with regulatory and clinical hurdles, the potential upside could be transformative for rare disease patients.
Looking ahead, Werner shares that Alltrna may expand its platform to address other genetic mutations like frameshift and missense mutations. She also hints at the company’s long-term strategy, which includes continuing to build and diversify its pipeline, with the possibility of future partnerships and an IPO. The ultimate vision? To develop a new standard for genetic disease treatment using the untapped potential of tRNA biology.
Curious to learn more about how Alltrna plans to revolutionize the treatment landscape for rare genetic diseases? Tune into the full episode of Raising Biotech for exclusive insights from Michelle Werner and Dr. David Weinstein.
[This episode was published on 19 December 2023]